Yoshida Homare, Kitaichi Takashi, Urata Masahisa, Kurobe Hirotsugu, Kanbara Tamotsu, Motoki Tatsuo, Kitagawa Tetsuya
Department of Cardiovascular Surgery, University of Tokushima Graduate School, Tokushima, Japan.
Ann Thorac Surg. 2009 Aug;88(2):418-24. doi: 10.1016/j.athoracsur.2009.04.105.
We investigated the effects and possible mechanism of syngeneic bone marrow mononuclear cell (BM-MNC) transplantation on pulmonary arterial hypertension induced by monocrotaline.
Monocrotaline (80 mg/kg body weight) was administrated to C57BL/6 mice, and pulmonary arterial hypertension was induced 4 weeks later. Bone marrow mononuclear cells harvested from syngeneic donor mice were injected intravenously into those mice 4 weeks after monocrotaline administration. The ratio of right ventricular to septum plus left ventricular weight, the number of small pulmonary arteries, and medial thickness of pulmonary arteries were measured. Western immunoblotting of the lung tissue was performed to observe vascular endothelial growth factor and its receptor expression 1 week after BM-MNC transplantation. Vascular endothelial growth factor receptor-2 inhibitor was administered to pulmonary arterial hypertension mice simultaneously with BM-MNC transplantation.
The ratio of right ventricular to septum plus left ventricular weight increased, the number of pulmonary arteries decreased, and medial thickness increased significantly 4 weeks after monocrotaline injection compared with those of vehicle-injected mice. These indices of monocrotaline-injected mice improved significantly 4 weeks after BM-MNC transplantation compared with those of mice at 8 weeks after monocrotaline injection (0.22 +/- 0.02 versus 0.31 +/- 0.02; 17.1 +/- 2.6 versus 8.2 +/- 1.7; 7.7% +/- 2.2% versus 20% +/- 2.1%, respectively; p < 0.01). However, BM-MNCs were not incorporated into the lung at 1 week after transplantation, and significant vascular endothelial growth factor upregulation and without receptor expression was observed in lung tissue 1 week after transplantation. Improvement of pulmonary arterial hypertension was inhibited by simultaneous administration of vascular endothelial growth factor receptor-2 inhibitor with BM-MNC transplantation.
These results indicate that syngeneic BM-MNC transplantation improves monocrotaline-induced pulmonary arterial hypertension by favorable pulmonary artery remodeling through vascular endothelial growth factor upregulation.
我们研究了同基因骨髓单个核细胞(BM-MNC)移植对野百合碱诱导的肺动脉高压的影响及可能机制。
将野百合碱(80mg/kg体重)给予C57BL/6小鼠,4周后诱导肺动脉高压。在给予野百合碱4周后,将从同基因供体小鼠采集的骨髓单个核细胞静脉注射到这些小鼠体内。测量右心室与室间隔加左心室重量的比值、小肺动脉数量和肺动脉中层厚度。在BM-MNC移植1周后,对肺组织进行蛋白质免疫印迹,以观察血管内皮生长因子及其受体表达。在BM-MNC移植的同时,将血管内皮生长因子受体-2抑制剂给予肺动脉高压小鼠。
与注射溶剂的小鼠相比,注射野百合碱4周后,右心室与室间隔加左心室重量的比值增加,肺动脉数量减少,中层厚度显著增加。与注射野百合碱8周后的小鼠相比,BM-MNC移植4周后,注射野百合碱小鼠的这些指标显著改善(分别为0.22±0.02对0.31±0.02;17.1±2.6对8.2±1.7;7.7%±2.2%对20%±2.1%;p<0.01)。然而,移植1周后BM-MNC未整合到肺中,移植1周后肺组织中观察到血管内皮生长因子显著上调且无受体表达。血管内皮生长因子受体-2抑制剂与BM-MNC移植同时给药可抑制肺动脉高压的改善。
这些结果表明,同基因BM-MNC移植通过上调血管内皮生长因子促进肺动脉重塑,从而改善野百合碱诱导的肺动脉高压。